A Phase 2 interventional study of SAR440340 and Dupilumab in Asthma, sponsored by Sanofi. Completed at 71 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-14.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.
Among the 37 studies in Asthma by Sanofi, this one is the 23rd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 11 in phase 2, and was the 17th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Canada, France and 3 more countries
Ages 6+
Sanofi · Sites in United States, Argentina, Belgium and 18 more countries
Ages 18+
Sanofi · Sites in United States, Argentina, Brazil and 13 more countries
Ages 2–5
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 296 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 450 across the 31 interventional studies, 144 across the 5 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Asthma by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06676319SanofiStudy of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Asthma by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.
Secondary Objectives:
To evaluate the effects of SAR440340/REGN3500 and coadministration of SAR440340 and dupilumab, compared with placebo, on forced expiratory volume in 1 second (FEV1).
To evaluate the effects of coadministration of SAR440340 and dupilumab, compared with SAR440340 and compared with dupilumab, on FEV1.
To assess safety and tolerability of SAR440340 alone and in coadministration with dupilumab.
The total duration of the study (per participant) was approximately 36 weeks, including 4 weeks screening, 12 weeks treatment, and 20 weeks post-treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 injections of SAR440340 300 milligram (mg) along with 1 injection of dupilumab placebo, subcutaneous (SC) once every 2 weeks (Q2W) for 12 weeks.
Drug: SAR440340 · Drug: Fluticasone or Fluticasone/salmeterol combination · Drug: Placebo for dupilumab
Participants received 1 injection of dupilumab 300 mg along with 2 injections of SAR440340 placebo, SC Q2W for 12 weeks.
Drug: Dupilumab · Drug: Fluticasone or Fluticasone/salmeterol combination · Drug: Placebo for SAR440340
Participants received 2 injections of SAR440340 300 mg along with 1 injection of dupilumab 300 mg, SC Q2W for 12 weeks.
Drug: SAR440340 · Drug: Dupilumab · Drug: Fluticasone or Fluticasone/salmeterol combination
Participants received 2 SC injections of SAR440340 placebo along with 1 SC injection of dupilumab placebo Q2W for 12 weeks.
Drug: Fluticasone or Fluticasone/salmeterol combination · Drug: Placebo for SAR440340 · Drug: Placebo for dupilumab
Pharmaceutical form: Solution for Injection, Route of administration: SC
Also known as: REGN3500
Pharmaceutical form: Solution for Injection, Route of administration: SC
Also known as: SAR231893 (REGN668)
Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Pharmaceutical form: Solution for Injection, Route of administration: SC
Pharmaceutical form: Solution for Injection, Route of administration: SC
Percentage of Participants With Loss of Asthma Control
An LOAC event during the 12-week treatment period was a deterioration of asthma defined as any of the following: a) 30 percent (%) or greater reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days; b) greater than or equal to (\>=) 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; c) increase in inhaled corticosteroid (ICS) \>=4 times the last prescribed ICS dose (or \>=50% of the prescribed ICS dose at Baseline if background therapy withdrawal completed); d) required use of systemic (oral and/or parenteral) steroid treatment; e) required hospitalization or emergency room visit.
Time frame: From Baseline up to Week 12
Change From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Pre-bronchodilator FEV1 refers to the spirometry performed after a wash period of bronchodilators (i.e., not earlier than 6 hours) after the last dose of albuterol/salbutamol or levalbuterol/levosalbutamol from a primed meter dose inhaler and withholding the last dose of long-acting β2 adrenergic agonist (LABA) for at least 12 hours, and prior to administration of study drug.
Time frame: Baseline, Week 12
Change From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Post-bronchodilator FEV1 refers to the spirometry performed within 30 minutes after administration of bronchodilator.
Time frame: Baseline, Week 12
The study was conducted from 12-March-2018 to 7-August-2019. Participants were screened at 70 centers across 8 countries, out of which 68 centers randomized at least 1 participant.
| Milestone | Placebo | SAR440340 300 mg | SAR440340 + Dupilumab | Dupilumab 300 mg |
|---|---|---|---|---|
| Started | 74 | 73 | 74 | 75 |
| Treated | 74 | 73 | 74 | 74 |
| Completed | 41 | 55 | 47 | 56 |
| Not completed | 33 | 18 | 27 | 19 |
| Withdrew: Adverse event (ae) | 3 | 0 | 2 | 0 |
| Withdrew: Loss of asthma control (loac) | 28 | 16 | 20 | 14 |
| Withdrew: Withdrawal by participant | 1 | 1 | 3 | 2 |
| Withdrew: Other- unspecified | 1 | 1 | 2 | 1 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 0 | 1 |
| Withdrew: Randomized and not treated | 0 | 0 | 0 | 1 |
An LOAC event during the 12-week treatment period was a deterioration of asthma defined as any of the following: a) 30 percent (%) or greater reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days; b) greater than or equal to (\>=) 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; c) increase in inhaled corticosteroid (ICS) \>=4 times the last prescribed ICS dose (or \>=50% of the prescribed ICS dose at Baseline if background therapy withdrawal completed); d) required use of systemic (oral and/or parenteral) steroid treatment; e) required hospitalization or emergency room visit.
| percentage of participants | Placebo | SAR440340 300 mg | SAR440340 + Dupilumab | Dupilumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants With Loss of Asthma Control | 40.5 | 21.9 | 27.0 | 18.9 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Pre-bronchodilator FEV1 refers to the spirometry performed after a wash period of bronchodilators (i.e., not earlier than 6 hours) after the last dose of albuterol/salbutamol or levalbuterol/levosalbutamol from a primed meter dose inhaler and withholding the last dose of long-acting β2 adrenergic agonist (LABA) for at least 12 hours, and prior to administration of study drug.
| liters | Placebo | SAR440340 300 mg | SAR440340 + Dupilumab | Dupilumab 300 mg |
|---|---|---|---|---|
| Change From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | 0.06 ± 0.35 | 0.11 ± 0.34 | 0.06 ± 0.37 | 0.14 ± 0.43 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Post-bronchodilator FEV1 refers to the spirometry performed within 30 minutes after administration of bronchodilator.
| liters | Placebo | SAR440340 300 mg | SAR440340 + Dupilumab | Dupilumab 300 mg |
|---|---|---|---|---|
| Change From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second | -0.02 ± 0.27 | -0.00 ± 0.33 | 0.06 ± 0.41 | 0.09 ± 0.42 |
Collected over From first administration of IMP up to the final visit (Week 32) regardless of seriousness or relationship to IMP. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/74 (0%) | 3/74 (4.1%) | 31/74 (41.9%) |
| SAR440340 300mg | 0/73 (0%) | 3/73 (4.1%) | 29/73 (39.7%) |
| SAR440340 + Dupilumab | 0/74 (0%) | 2/74 (2.7%) | 26/74 (35.1%) |
| Dupilumab 300mg | 1/74 (1.4%) | 3/74 (4.1%) | 28/74 (37.8%) |
| Event | Placebo | SAR440340 300mg | SAR440340 + Dupilumab | Dupilumab 300mg |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/74 | 1/73 | 0/74 | 0/74 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/74 | 1/73 | 0/74 | 0/74 |
| Deep Vein ThrombosisVascular disorders | 0/74 | 1/73 | 0/74 | 0/74 |
| Aortic Valve IncompetenceCardiac disorders | 0/74 | 0/73 | 0/74 | 1/74 |
| Cholecystitis AcuteHepatobiliary disorders | 1/74 | 0/73 | 0/74 | 0/74 |
| Abscess JawInfections and infestations | 0/74 | 0/73 | 0/74 | 1/74 |
| Pyelonephritis AcuteInfections and infestations | 0/74 | 0/73 | 1/74 | 0/74 |
| Alcohol PoisoningInjury, poisoning and procedural complications | 0/74 | 0/73 | 0/74 | 1/74 |
| Alanine Aminotransferase IncreasedInvestigations | 0/74 | 0/73 | 1/74 | 0/74 |
| Vascular EncephalopathyNervous system disorders | 1/74 | 0/73 | 0/74 | 0/74 |
| Event | Placebo | SAR440340 300mg | SAR440340 + Dupilumab | Dupilumab 300mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/74 | 13/73 | 8/74 | 9/74 |
| HeadacheNervous system disorders | 7/74 | 6/73 | 5/74 | 10/74 |
| Injection Site ReactionGeneral disorders | 4/74 | 1/73 | 5/74 | 4/74 |
| Urinary Tract InfectionInfections and infestations | 2/74 | 1/73 | 5/74 | 3/74 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 5/74 | 3/73 | 5/74 | 2/74 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/74 | 1/73 | 0/74 | 1/74 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 1/74 | 3/73 | 0/74 | 5/74 |
| NauseaGastrointestinal disorders | 2/74 | 4/73 | 2/74 | 1/74 |
| Back PainMusculoskeletal and connective tissue disorders | 1/74 | 4/73 | 2/74 | 3/74 |
| Upper Respiratory Tract Infection BacterialInfections and infestations | 2/74 | 1/73 | 4/74 | 2/74 |
Analysis was performed on randomized population that included any participant who had signed informed consent and had been allocated to a randomized treatment regardless of whether the treatment kit was used.
| Age, Continuous(years) | Placebo | SAR440340 300 mg | SAR440340 + Dupilumab | Dupilumab 300 mg | Total |
|---|---|---|---|---|---|
| Mean | 47.0 ± 11.4 | 49.0 ± 13.9 | 49.1 ± 12.0 | 51.3 ± 12.7 | 49.1 ± 12.6 |
| Sex: Female, Male(Participants) | Placebo | SAR440340 300 mg | SAR440340 + Dupilumab | Dupilumab 300 mg | Total |
|---|---|---|---|---|---|
| Female | 47 | 50 | 51 | 41 | 189 |
| Male | 27 | 23 | 23 | 34 | 107 |
| Race (NIH/OMB)(Participants) | Placebo | SAR440340 300 mg | SAR440340 + Dupilumab | Dupilumab 300 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 1 | 1 | 4 |
| Asian | 0 | 2 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 2 | 0 | 6 |
| White | 71 | 68 | 69 | 73 | 281 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2018 to primary completion in Mar 2019, 12 months.
Results were first posted in Mar 2022, 3 years after primary completion. A results delay was requested in May 2020.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 12 months is below that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itepekimab